Compare Conagra Brands Inc (CAG) vs Hims and Hers Health Inc (HIMS) Price & Performance

Conagra Brands (CAG) trades at $14.78, down 2.18% today, with a bearish technical signal and neutral oscillators. The company reported a net income margin of -16.99% for 2026, with revenue declining to $11.3B, while 2025 showed stronger profitability. Recent corporate actions include a dividend cut to $0.18 and leadership changes under CEO John Brase, aiming to streamline operations and reduce debt.

The outlook is mixed: low valuation metrics (P/E 10.06, P/S 0.63) offer downside support, but weak growth and margin pressures pose risks. Analyst consensus is cautious with a $13.67 price target, and institutional sentiment is divided amid ongoing turnaround efforts. Key risks include consumer pushback on pricing and execution challenges under new management.

HIMS stock declined 7.11% to $29.51 following mixed Q2 2026 results, where revenue beat expectations but the company posted a wider-than-expected loss. The technical picture is neutral with bearish moving average signals, while fundamentals show strong revenue growth but deteriorating margins. Recent news highlights margin pressure from GLP-1 drug investments and an FTC investigation, creating investor uncertainty despite raised revenue guidance.

The outlook remains cautious as strong subscriber growth and AI initiatives are offset by profitability challenges and regulatory scrutiny. Investment opportunity exists in the company's expanding global footprint and raised revenue targets, but risks include margin compression, negative cash flow trends, and ongoing legal investigations that could pressure the stock near-term.